Nordic Nanovector has announced that Lars Nieba has been appointed interim Chief Executive Officer with immediate effect.
Dr Nieba, who is currently the company’s Chief Technology Officer, replaces Eduardo Bravo who as of today has left Nordic Nanovector to pursue other career opportunities.
“The Board is very pleased to appoint Lars Nieba as Nordic Nanovector’s interim CEO. We believe that his significant operational, development and product supply expertise will be crucial as we work towards completing the PARADIGME study and prepare for the planned filing for Betalutin® with the FDA. On behalf of the Board I would like to thank Eduardo for his contribution as CEO,” says Jan H. Egberts, MD, Chairman of Nordic Nanovector.
Various leadership roles
Nieba joined Nordic Nanovector on 1 December 2019 from Bayer AG where he served in various operational and strategic roles, Nieba was most recently responsible for driving Bayer’s Chemistry, Manufacturing and Controls (CMC) strategy for biologicals. He joined Bayer in 2016 following 13 years at F. Hoffmann-La Roche Ltd., where he held various leadership roles in clinical, operations, supply planning, biologics technology and technical business development. Prior Nieba worked for Cytos Biotechnology where he served as Head of Therapeutic Vaccine Research.
Nieba gained a PhD from the Max-Planck-Institute for Biochemistry, München and Institute for Biochemistry at the University of Zürich, and an Executive MBA from the University of St. Gallen, Switzerland.